EHA 2022 | Campus ALL updates: the safety and efficacy of daratumumab for the treatment of ALL
Sabina Chiaretti
• 12 Jun 2022
Sabina Chiaretti, MD, PhD, Sapienza University of Rome, Rome, Italy, shares some results from a study evaluating the safety and efficacy of daratumumab for the treatment of acute lymphoblastic leukemia (ALL). Patients with both B-ALL and T-ALL were included in this study, and Dr Chiaretti highlights the response rates observed, and further explains that daratumumab may have a place in the T-ALL treatment landscape. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Amgen, Incyte, Novartis, AbbVie, Gilead.
